Biotime acquires Robert Lanza of ACTC, and made CEO of ReCyte Therapeutics.
With a monopoly on the hESC gold standard and Jeffery Janus from ISCO selling our products, I'd say research profits will be kickin in early 2014.
The discovery of iPS cells raised the possibility that ES cell research would no longer be necessary, there- by circumventing the ethical issues present in em- bryonic research. To date, this has not been the case: the stem cell field continues to rely on both ES and iPS cell research to progress the understanding of pluripotency and its potential applications (Smith and Blackburn, 2012). Further, it has become clear that iPS cell research is not free of ethical consider- ations (Hug and Hermeren, 2011). For instance, the potential of these cells to generate sperm and egg cells, or even a whole new individual, raises new eth- ical questions about the status of the cells themselves and how they may be used.
The previous post is a stem cell research study brought forth by the StemCell Summit. It is based on statistics from 2008-2012. True there is an increase in ips cell and decrease in hESC research. 99.9% of companies and institutions are competing in the race to research, patent and use IPS and adult stem cells for future medical therapies. As for 'embryonic' stem cells BTX takes most of the pie.
Biotimes CEO Dr. West had the vision and smarts to know that hESC's research viability would eventually be held above all because of it being the 'original.'
I predict an increase in hESC research trend in 2013 and beyond. Only if it makes up for 0.2 of worldwide stem cell research, it will benefit BTX tremendously being that BTX is the leading holder of hESC research products.
Let me preface by acknowledging PS cell/Adult cell technology will primarily make up the majority of research and eventually therapeutics, that's a no brainer. The good news for Biotime is that they have leading IP regarding both IPS & stem cell reprogramming.
On the research front Biotime is by far the WORLDS leading holder of human embryonic stem cell products.
in fact, BTX has a monopoly on hESC IP, make no mistake it will start to become clear over the next few years that hESC's are the 'gold standard' and will become a huge part of scientific literature when comparing the cause and effects of stem cell propagation on human biology.
Here is a blurb from todays news story regarding the increase in stem cell research:
"Research into the medical uses of stem cells is growing at a rate of 7% a year, or twice the world’s average growth in research of 2.9%, according to a new report.
In the recent field of induced pluripotent stem cells, awarded the Nobel Prize in physiology or medicine last year, the annual growth rate since 2008 is an astonishing 77%, the report states."
Dr. West went on to say that to get these different types of stem cells into the clinic, and approved by the FDA, researchers will fully need to understand all aspects of the biology of these cells. An identification and understanding of any contaminating cells will also be essential to success in this field. The question to ask is “What is in the syringe?”
Unlike recombinant DNA, continued Dr. West, the contaminants in pluripotent stem cells are alive and may make things that are undesirable at the intended point of therapy. For example, you might have a bioreactor full of cells that are making heart muscle to regenerate heart function in a patient. But you have to be careful that your cells are not contaminated with neural crest cells from the head area which could generate a tooth along with the heart muscle.
“These contaminants, if you do not remove them, can lead to years of delay in filing an IND and a runup in costs as you try to identify these cells,” explained Dr. West.
The major problem in identifying them, according to Dr. West, is that no one has ever mapped the molecular markers or even a rudimentary cell ontology tree, i.e., mapped out the tree from the fertilized egg to the cells of the human body.
“If [there were] a detailed map of all the cellular and molecular components of life from the fertilized egg to adulthood, and then databased in a manner to the information in the human genome, medicine would be the true beneficiary,” added Dr. West. “That’s why we have made this call for an international initiative.”
GEN News HighlightsMore
Dec 5, 2013
Stem Cell Leaders Call for Human Embryome Project
Just as an international consortium was formed to map and sequence the human genome, now a group of stem cell and regenerative medicine scientists say it’s critical that such an effort be ramped up to do a similar project focused on the human embryome.
This was the key message of a panel discussion, “From Mapping the Genome to Mapping the Embryome: The Urgent Need for an International Initiative,” moderated by Michael West, Ph.D., CEO of Biotime. It took place at the World Stem Cell Summit, which is taking place this week in San Diego.
“It is becoming increasingly clear in regenerative medicine that pluripotent stem cells, embryonic stem cells, and IPs cells will be as fundamentally important to medicine as was DNA. Maybe even bigger because you can genetically engineer these cells,” said Dr. West.
Dr. West and his colleagues adamantly believe that there needs to be a large international effort aimed at mapping the cellular and molecular basis of all human life starting with the fertilized egg and working its way up to the body of the adult. This is what it is termed the embryome.
“The opportunity presented by pluripotent stem cells to manufacture for the first time in the history of medicine all of the cellular components of the human body on an industrial scale is at once both an opportunity and a challenge,” said Dr. West. “The opportunity is to build a new field we call regenerative medicine in which many currently incurable diseases are treated with cells capable of regenerating tissues afflicted with disease. The challenge relates to the complexity of the cell types in the body and our ability to manufacture products with precisely defined compositions for human clinical use.”
realtruf.....you lose, your an idiot. I'm putting you on 'ignore' as well. I depend on these boards for good information not lying hedge fund morons like yourself, captJ & BB. All 'ignored from now on.
Life Technologies aren't:
-StemPro® hESC SFM Components:
-StemPro® hESC Supplement
-DMEM⁄F-12 with GlutaMAX™ medium
-Bovine serum albumin 25% (BSA)
-Additional components required for complete medium (need to be purchased separately):
-FGF BASIC (full length) REC HU (Cat. no. PHG0261)
-2-Mercaptoethanol (Cat. no. 21985-023)
There is one company pioneering this effort......Biotime.